Exhibit 99.3

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

The following unaudited pro forma condensed combined financial statements of Hologic, Inc. (“Hologic”) have been prepared to give effect to the acquisition by Hologic of Gen-Probe Incorporated (“Gen-Probe”) (the “Gen-Probe Acquisition”). The unaudited pro forma condensed combined balance sheet combines the unaudited condensed balance sheets of Hologic and Gen-Probe as of June 23, 2012 and gives effect to the Gen-Probe Acquisition as if it had been completed on that date. The unaudited pro forma condensed combined statement of operations for the nine months ended June 23, 2012 and year ended September 24, 2011 combines the historical results of Hologic and Gen-Probe and gives effect to the Gen-Probe Acquisition as if it had occurred on September 26, 2010. Hologic and Gen-Probe have different fiscal year end dates. While the difference is more than 93 days, Gen-Probe’s results for its fiscal year ended December 31, 2011 have been used to prepare the unaudited pro forma condensed combined statement of operations for the year ended September 24, 2011 because the difference in fiscal periods is one quarter. As a result, Gen-Probe’s results of operations for the three months ended December 31, 2011 are included in the unaudited pro forma condensed combined statements of operations for both the year ended September 24, 2011 and the nine months ended June 23, 2012. Gen-Probe’s summary financial results for the three months ended December 31, 2011, which are included in both of these periods, are as follows (in thousands):

The historical consolidated financial information of Hologic and Gen-Probe has been adjusted in the unaudited pro forma condensed combined financial statements to give effect to pro forma events that are (1) directly attributable to the Gen-Probe Acquisition and the related debt financing, (2) factually supportable, and (3) with respect to the statements of operations, expected to have a continuing impact on the combined results. The unaudited pro forma condensed combined financial statements presented are based on the assumptions and adjustments described in the accompanying notes. The unaudited pro forma condensed combined financial statements are presented for illustrative purposes and do not purport to represent what the financial position or results of operations would actually have been if the Gen-Probe Acquisition occurred as of the dates indicated or what such financial position or results of operations will be for any future periods. The actual financial position or results of operations reported by the combined company in periods following the Gen-Probe Acquisition may differ significantly from those reflected in these unaudited pro forma condensed combined financial statements for a number of reasons, including but not limited to the impact and benefits of the Gen-Probe Acquisition, cost savings from operating efficiencies, synergies and the incremental costs incurred in successfully integrating and operating the Gen-Probe business. There were no transactions between Hologic and Gen-Probe during the periods presented in the unaudited pro forma condensed combined financial statements that would need to be eliminated. The unaudited pro forma condensed combined financial statements are based upon the respective historical consolidated financial information of Hologic and Gen-Probe for the periods presented, and should be read in conjunction with:

The unaudited pro forma condensed combined financial information was prepared using the purchase method of accounting. As such, the unaudited pro forma condensed combined balance sheet reflects the consideration paid by Hologic to acquire Gen-Probe and has been allocated to the assets acquired and liabilities assumed based upon management’s preliminary estimate of their respective fair values as of the date of the Gen-Probe Acquisition. Any differences between the estimated fair value of the consideration paid and the estimated fair value of the assets and liabilities acquired is recorded as goodwill. The amounts allocated to the acquired assets and liabilities in the unaudited pro forma condensed combined financial statements are based on management’s preliminary valuation estimates. Definitive allocations will be performed and finalized based on certain valuations and other studies that are currently being performed by Hologic with the services of an outside valuation specialist. Accordingly, the purchase price allocation adjustments and related amortization reflected in the following unaudited pro forma condensed combined financial statements are preliminary, have been made solely for the purpose of preparing these statements and are subject to revision based on a final determination of fair value upon obtaining all available information to complete the valuation of acquired assets and liabilities. For example, if the fair value of the definite-lived intangible assets changed by 10%, there would be a corresponding $19.0 million annual increase or decrease in amortization expense.

1

The pro forma adjustments are preliminary and have been made solely for the purpose of providing unaudited pro forma condensed combined financial statements. Differences between these preliminary estimates and the final purchase accounting will occur and these differences could have a material impact on the accompanying unaudited pro forma condensed combined financial statements and the combined company’s future results of operation and financial position.

The unaudited pro forma condensed combined statements of operations also include certain purchase accounting adjustments, including items expected to have a continuing impact on the combined results, such as increased depreciation and amortization expense on acquired tangible and intangible assets, increased interest expense on the debt incurred to complete the Gen-Probe Acquisition, decreased interest income related to the reduction in cash and marketable securities used to complete the Gen-Probe Acquisition and the tax impact related to these pro forma adjustments.

The unaudited pro forma condensed combined financial statements reflect the borrowing of $3.5 billion to fund the Gen-Probe Acquisition, consisting of senior secured term loan facilities in the aggregate principal amount of $2.5 billion and the sale of $1.0 billion in principal amount of senior notes. Fees and expenses incurred in connection with the financing and applicable interest rates under the term loans have been estimated for the purposes of preparing these unaudited pro forma condensed combined financial statements and are subject to change based on the related fees and expenses actually incurred and market changes that may result in a change in the actual interest rate applied to borrowings under the term loan facilities as compared to the rates assumed. For example, if interest rates increase or decrease by .125% on the amounts outstanding under the senior secured term loan facilities compared to the rates assumed, annual pro forma income before the provision for income taxes would increase or decrease approximately $3.1 million. This calculation excludes the senior notes as the interest rate on the notes is fixed at 6.25%.

The unaudited pro forma condensed combined statements of operations do not reflect certain amounts resulting from the Gen-Probe Acquisition because Hologic considers them to be of a non-recurring nature and are anticipated to be included in the income of Hologic within 12 months succeeding the transaction. These amounts include the estimated reduction in revenue of approximately $34.8 million to record an estimated receivable for future amounts due from Novartis for which there is no future contractual performance obligation related to Gen-Probe’s revenue-sharing arrangement, the cost of revenue impact of approximately $71.3 million for the write up of inventory to fair value, the reduction of deferred revenue of approximately $4.4 million for amounts that would not represent a contractual performance obligation at the close of the transaction, and approximately $61.6 million of acquisition-related fees and expenses. The unaudited pro forma condensed combined statements of operations do not include the impact of any revenue, cost or other operating synergies that may result from the Gen-Probe Acquisition or any related restructuring or other costs necessary to achieve anticipated cost savings, operating synergies and revenue enhancements. Cost savings, if achieved, could result from streamlining of product development initiatives, rationalization of overlapping functional areas, such as sales and marketing and certain general and administrative functions, and consolidation of manufacturing resources and field service and support.

Based on Hologic’s preliminary review of Gen-Probe’s summary of significant accounting policies disclosed in Gen-Probe’s financial statements, other than a reclassification of certain Gen-Probe expenses to cost of revenue discussed in the accompanying notes to the unaudited pro forma condensed combined financial statements, the nature and amount of any adjustments to the historical financial statements of Gen-Probe to conform their accounting policies to those of Hologic are not expected to be significant. Further review of Gen-Probe’s accounting policies and financial statements may result in required revisions to Gen-Probe’s policies and classifications to conform to Hologic’s.

2

Unaudited Pro Forma Condensed Combined Balance Sheet

As of June 23, 2012

(In thousands)

3

Unaudited Pro Forma Condensed Combined Statement of Operations

Year Ended September 24, 2011

(In thousands, except per share data)

4

Unaudited Pro Forma Condensed Combined Statement of Operations

Nine Months Ended June 23, 2012

(In thousands, except per share data)

5

Notes to Unaudited Pro Forma Condensed Combined Financial Statements

(In thousands, except per share information)

On August 1, 2012, pursuant to the terms of an Agreement and Plan of Merger dated as of April 29, 2012, Hologic completed the acquisition of Gen-Probe. At the effective time and as a result of the acquisition, each share of common stock of Gen-Probe issued and outstanding immediately prior to the effective time of the Gen-Probe Acquisition was automatically converted into the right to receive $82.75 in cash, without interest and less any applicable withholding taxes (the “Merger Consideration”).

In addition, each outstanding Gen-Probe stock option, other than options granted on or after February 8, 2012, were cancelled and converted into the right to receive an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price for each share subject to the applicable option. With respect to Gen-Probe stock options granted on or after February 8, 2012, each such option was converted pursuant to the merger agreement into a stock option to acquire shares of Hologic common stock on the same terms and conditions as were in effect immediately prior to the completion of the Gen-Probe Acquisition. The number of shares of Hologic common stock underlying each converted Gen-Probe stock option was determined by multiplying the number of shares of Gen-Probe common stock subject to such stock option immediately prior to the completion of the Gen-Probe Acquisition by the option exchange ratio, as defined in the Agreement and Plan of Merger. The exercise price per share of each converted Gen-Probe stock option was determined by dividing the per share exercise price of such stock option by the option exchange ratio. The fair value of the assumed stock options, whether vested or unvested, is recorded as part of the purchase consideration transferred, as detailed in Note 3(b), to the extent that pre-acquisition services have been rendered. The remainder of the fair value of the unvested stock options will be recorded as compensation expense in Hologic’s post-acquisition financial statements over the remaining vesting period following the Gen-Probe Acquisition completion date.

With respect to Gen-Probe performance shares, the performance periods applicable to each Gen-Probe performance share outstanding immediately prior to the effective time terminated immediately prior to the effective time, and 150% of the target number of Gen-Probe performance shares subject to each such Gen-Probe performance share award with respect to such performance period fully vested as of the effective time and were converted at the effective time into the right to receive the Merger Consideration for each performance share. With respect to Gen-Probe restricted stock, the vesting restrictions of each such share outstanding immediately prior to the effective time lapsed as of the effective time, and each such share of restricted stock was cancelled and converted into the right to receive the Merger Consideration for each share of restricted stock.

In connection with completing the Gen-Probe Acquisition, Hologic concurrently entered into (i) a senior secured term loan “A” facility in an aggregate principal amount of $1 billion, or the “Term Loan A Facility,” (ii) a senior secured term loan “B” facility in an aggregate principal amount of $1.5 billion, or the “Term Loan B Facility” and, together with the Term Loan A Facility, the “Term Loan Facilities,” and (iii) a revolving credit facility with aggregate revolving commitments of $300 million, or the “Revolving Credit Facility,” and together with the Term Loan Facilities, the “New Credit Facilities,” in each case among Hologic, as borrower, the guarantors thereunder, Goldman Sachs Bank USA, as administrative agent, and the other agents and lenders party thereto. In addition, concurrent with completing the Gen-Probe Acquisition, Hologic sold $1 billion of 6.25% senior notes due 2020 in a private placement pursuant to Rule 144A under the Securities Act of 1933, as amended, and outside the United States in accordance with Regulation S under the Securities Act of 1933, as amended.

The unaudited pro forma condensed combined financial statements of Hologic have been prepared to give effect to the Gen-Probe Acquisition. The unaudited pro forma condensed combined balance sheet combines the unaudited condensed balance sheets of Hologic and Gen-Probe as of June 23, 2012 and gives effect to the Gen-Probe Acquisition as if it had been completed on that date. The unaudited pro forma condensed combined statement of operations for the nine months ended June 23, 2012 and year ended September 24, 2011 combines the historical results of Hologic and Gen-Probe and gives effect to the Gen-Probe Acquisition as if it had occurred on September 26, 2010. Hologic and Gen-Probe have different fiscal year end dates. While the difference is more than 93 days, Gen-Probe’s results for the year ended December 31, 2011 have been used to prepare the unaudited pro forma condensed combined statement of operations for the year ended September 24, 2011 because the difference in fiscal periods is one quarter. As a result, Gen-Probe’s results of operations for the three months ended December 31, 2011 are included in the unaudited pro forma condensed combined statements of operations for both the year ended September 24, 2011 and the nine months ended June 23, 2012. Gen-Probe’s summary financial results for the three months ended December 31, 2011, which are included in both of these periods, are as follows:

6

The unaudited pro forma condensed combined financial information was prepared using the purchase method of accounting. As such, the unaudited pro forma condensed combined balance sheet reflects the consideration paid by Hologic to acquire Gen-Probe and has been allocated to the assets acquired and liabilities assumed based upon management’s preliminary estimate of their respective fair values as of the date of the Gen-Probe Acquisition. Any differences between the fair value of the consideration paid and the estimated fair value of the assets and liabilities acquired is recorded as goodwill. The amounts allocated to the acquired assets and liabilities in the unaudited pro forma condensed combined financial statements are based on management’s preliminary valuation estimates. Definitive allocations will be performed and finalized based on certain valuations and other studies that are currently being performed by Hologic with the services of an outside valuation specialist. Accordingly, the purchase price allocation adjustments and related amortization reflected in the following unaudited pro forma condensed combined financial statements are preliminary, have been made solely for the purpose of preparing these statements and are subject to revision based on a final determination of fair value after obtaining all available information to complete the valuation of acquired assets and liabilities.

Acquisition-related transaction costs (e.g., investment banker, advisory, legal, valuation, and other professional fees) and certain acquisition restructuring and related charges are not included as a component of consideration transferred but are required to be expensed as incurred. The unaudited pro forma condensed combined balance sheet reflects the $61.6 million of estimated acquisition-related transaction costs of both companies as a reduction of cash with a corresponding decrease in retained earnings. These costs are not presented in the unaudited pro forma condensed combined statement of operations because they will not have a continuing impact on the combined results.

The unaudited pro forma condensed combined financial statements do not reflect the expected realization of approximately $75 million in annual cost savings by the end of the third year following the Gen-Probe Acquisition or anticipated costs Hologic will incur to realize such synergies, including retention payments. These savings are expected to result from streamlining of product development initiatives, rationalization of overlapping functional areas, such as sales and marketing and certain general and administrative functions, and consolidation of manufacturing resources and field service and support. Although Hologic management expects that costs savings will result from the Gen-Probe Acquisition, there can be no assurance that these cost savings will be achieved.

The following represents the purchase price for Gen-Probe:

For purposes of this pro forma analysis, the above purchase price has been allocated based on a preliminary estimate of the fair value of net assets acquired.

7

Based upon a preliminary valuation analysis, for purposes of these pro forma combined condensed financial statements, the fair value of identified intangible assets and their weighted-average useful lives in years have been estimated as follows:

The preliminary fair value of the intangible assets has been estimated using the income approach in which the after-tax cash flows are discounted to present value. The cash flows are based on estimates used to price the transaction, and the discount rates applied were benchmarked with reference to the implied rate of return from the transaction model as well as the weighted average cost

8

of capital. Based on the preliminary valuation, the acquired intangible assets are comprised of existing technology of approximately $1.63 billion, representing five product families, in-process research and development of approximately $240.0 million, representing a number of projects, customer relationship assets of approximately $610.0 million, and trade-names of approximately $90.0 million.

The existing technology assets relate to currently marketed products and related instrument automation, and consideration was only given to products that have been approved by the FDA. In-process research and development projects relate to in-process projects that have not reached technological feasibility and have no alternative future use. The primary basis for determining technological feasibility of these projects is obtaining regulatory approval to market the underlying product, which primarily pertains to receiving approval to perform certain diagnostic testing on Gen-Probe’s instrumentation, such as the PANTHER and TIGRIS. Given the uncertainties inherent with product development and introduction, there can be no assurance that any of the combined company’s product development efforts will be successful on a timely basis or within budget, if at all.

These preliminary estimates of fair value and estimated useful lives may vary materially from the final acquisition accounting, and the difference could have a material impact on the accompanying unaudited pro forma condensed combined financial statements. A 10% change in the valuation of definite lived intangible assets would cause a corresponding $19.0 million annual increase or decrease in amortization expense. As Hologic completes its fair value analysis, additional information may be obtained by Hologic regarding the specifics of Gen-Probe’s intangible assets, and additional insight may be gained that could impact: (i) the estimated total value assigned to intangible assets, (ii) the estimated allocation of value between definite-lived and indefinite-lived intangible assets and/or (iii) the estimated weighted-average useful life of each category of intangible assets. The estimated intangible asset values and their useful lives could be impacted by a variety of factors that may become known as Hologic completes its final acquisition accounting.

The following pro forma adjustments are based on preliminary estimates, which may change as additional information is obtained:

(A) Reflects adjustments to cash related to the following:

(B) To adjust Gen-Probe’s tangible assets and liabilities to their estimated fair value, as follows:

9

10

(C) To record deferred taxes related to identified intangible assets and fair value adjustments, where required for step-up in basis for book purposes, at 38%, the estimated weighted average statutory tax rate, and the impact of adjusting deferred tax assets related to stock-based compensation. The adjustments to short-term tax assets and long-term deferred tax liabilities reflect the following:

(D) To record estimated income taxes receivable of $25.6 million in Gen-Probe’s recently filed tax returns as a result of tax deductions from the automatic exercise and sale of stock options, that were granted prior to February 8, 2012, and the acceleration and sale of performance shares and restricted stock awards at closing. In total, the gross tax deduction is estimated to be approximately $162 million. Per the terms of Gen-Probe’s equity awards, the unvested tranches of stock options granted prior to February 8, 2012 and all performance shares and restricted stock awards become vested in connection with a change-in-control. At June 30, 2012, the unrecognized stock compensation expense related to these awards was approximately $28.6 million, which was recognized in Gen-Probe’s statement of operations immediately before the Gen-Probe Acquisition was completed.

(E) To reflect the acquired identifiable intangible assets at estimated fair value and elimination of Gen-Probe’s historical intangible assets as follows:

(F) To reflect goodwill from the Gen-Probe Acquisition and elimination of Gen-Probe’s historical goodwill as follows:

(G) To reflect the increase in debt of $3.5 billion in aggregate principal, net of discounts of $23.8 million, incurred to complete the Gen-Probe Acquisition, consisting of senior secured term loan facilities in the aggregate principal amount of $2.5 billion and the sale of $1.0 billion in principal amount of 6.25% senior notes due 2020. The amount borrowed excludes a $300 million senior secured revolving credit facility that Hologic obtained as part of its senior secured facilities. Hologic used the borrowings under its term loan facilities, the proceeds from the sale of its senior notes and available combined cash and marketable securities of approximately $878.1 million to finance the Gen-Probe Acquisition, repay amounts outstanding under Gen-Probe’s existing revolving credit facility

11

and pay acquisition related fees and expenses. The acquired debt has been classified as short-term and long-term, net of applicable discounts, based on the required repayment provisions of the Term Loan Facilities. In connection with obtaining this financing, Hologic has paid financing fees to the lenders and incurred other costs directly related to the financing transaction. Accordingly, an aggregate of approximately $75.3 million of deferred financing costs, including underwriters’ fees, is reflected as an adjustment to increase other assets.

(H) To record the fair value of pre-combination services related to Gen-Probe’s stock options that were converted into Hologic stock options upon completion of the Gen-Probe Acquisition as purchase price. The fair value of Gen-Probe’s options was calculated pursuant to Accounting Standards Codification (“ASC”) Topic 718, Compensation-Stock Compensation, as required by ASC Topic 805, Business Combinations. Hologic utilized the Binomial Option Pricing Model to determine the fair value of these stock options and using the ratio of pre-combination services to the aggregate vesting period applied to the aggregate fair value to determine the amount allocable to the purchase price.

(I) To eliminate the historical stockholders’ equity accounts of Gen-Probe.

(J) To record estimated non-recurring acquisition related transaction costs of both companies aggregating $61.6 million.

(K) Adjustments to cost of revenue are comprised of the following:

(L) To record intangible asset amortization expense related to acquired developed technology intangible assets on a straight-line basis over a weighted average estimated life of 13 years. See Note 3(h) for additional information.

(M) To record depreciation expense of the estimated fair value adjustment related to Gen-Probe’s property, plant and equipment related to research and development over its estimated remaining useful life. See Note 4(B) and Note 3(g) for additional information.

(N) Adjustments to sales and marketing expenses are comprised of the following:

(O) Adjustments to general and administrative expenses are comprised of the following:

12

(P) Adjustments to amortization of intangible assets are comprised of the following:

(Q) Adjustments to interest income are comprised of the following:

(R) Adjustments to interest expense are comprised of the following:

13

based on the assumed rates set forth therein. Each of the Term Loan Facilities and the senior notes will carry different interest rates, with the Term Loan Facilities bearing interest at variable rates. Based on the borrowings and contemplated interest rates under the Term Loan Facilities and the rate of the senior notes, the initial weighted average annual interest rate was 4.64%, excluding underwriters’ fees and discounts. Including the underwriters discount, the initial weighted average annual interest rate was 4.80%. If the actual interest rate were to increase or decrease by .125% on the amounts outstanding under the Term Loan Facilities compared to the rates assumed, annual pro forma income before the provision for income taxes would increase or decrease approximately $3.1 million. This calculation excludes the senior notes as the interest rate on the notes is fixed at 6.25% The amortization of estimated deferred financing costs, including underwriters’ fees and discounts, of $16.0 million per year and the annual commitment fee of $1.5 million on the Revolving Credit Facility were also included to determine the total increase in interest expense. The amortization of deferred financing costs, including underwriters’ fees and discounts, was based on the assumed term of each of the Term Loan Facilities and the senior notes. The repayment of the estimated financing requirements was not assumed for any of the statement of operations periods presented.

(S) To record the tax benefit on pro forma loss before provision (benefit) for income taxes to reflect the estimated combined effective federal and state tax rate by applying 37.3% to the pro forma adjustments. Although not reflected in these unaudited pro forma condensed combined financial statements, the effective tax rate of the combined company could be significantly different depending on post-acquisition activities, including potential repatriation of earnings from subsidiaries outside the U.S. and geographical mix of taxable income affecting state and foreign taxes, among other factors. As Hologic completes the acquisition accounting for the Gen-Probe Acquisition and additional information becomes available, it is likely the applicable income tax rate will change. If the estimated effective rate were to change by 10%, the effect on the pro forma net loss for the year ended September 24, 2011 and nine months ended June 23, 2012 would be approximately $2.4 million and $3.6 million, respectively.

(T) To reflect the elimination of Gen-Probe’s weighted average shares outstanding. The impact of options issued in connection with the Gen-Probe Acquisition is anti-dilutive as there is a pro forma net loss for all periods presented.

(U) The pro forma condensed combined statements of operations do not reflect estimated transaction expenses to be incurred by Hologic of approximately $34.3 million, transaction expenses to be incurred by Gen-Probe of approximately $27.3 million, stock-based compensation expenses for the acceleration of vesting of outstanding stock options and restricted stock of approximately $28.6 million or the cost of revenue impact of approximately $71.3 million for the write up of inventory to fair value. The stock-based compensation charges were recorded by Gen-Probe in its fiscal third quarter of 2012.

14